Lighting the Way in COG with MATCH: Targeted Therapies in Pediatric CNS Tumors (C211)

5:00 – 6:00 pm Thursday, October 28

coglogoPediatric MATCH (Molecular Analysis for Therapy Choice) is a joint effort between the National Cancer Institute (NCI) and Children’s Oncology Group (COG) matching targeted therapies to specific tumor genomic sequencing in patients with relapsed or refractory solid tumors, non-Hodgkin lymphomas, brain tumors, and histiocytic disorders.

Pediatric MATCH uses validated next-generation sequencing targeted assay of more than 4,000 separate mutations across more than 140 genes. The study has 13 subprotocols with each subprotocol focusing on agent classifications. These agent classes include pan-TRK, FGFR, EZH2, MEK, PI3K/mTOR, ALK, BRAF, PARP, CDK4/6, ERK ½, IDH1, Farnesyl Transferase, and RET inhibitors. All of these inhibitors have been found to be important in a variety of pediatric cancers. Many of these classes have been trialed in pediatric central nervous system (CNS) tumors in various settings and have shown to have treatment effect, especially in tumors previously thought to be difficult to treat. Yet, within the pediatric CNS tumor arena, the most studied associated agents to date are vemurafenib (BRAF), palbociclib (CDK4/6), and selumetinib (MEK). The presentation will (1) provide an overview of Pediatric MATCH; (2) review BRAF, CD4/6K, and MEK pathways; and (3) review the agents’ side effects, and associated side-effect management, that nursing plays a key role in monitoring for and treating.